However, in experimental mouse models, Bevacizumab (Avastin, a recombinant humanized antibody that binds VEGF isoforms) treatment resulted in a transient remodeling of the tumor vasculature by increasing the number of matured (i.e., pericyte covered) vessels, decrease permeability, reduce IFP, and increase perfusion in neuroblastoma xenografts. The gene discussed is VEGFA; the disease is neuroblastoma.